

NeuroMetrix Reports DPNCheck Introduction at the Annual Meeting of the China Diabetes Society

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) today reported that DPNCheck®, a diagnostic test for peripheral neuropathy, will be introduced at the 20th Scientific Meeting of the Chinese Diabetes Society during November 16-19, 2016 in Xiamen, Fujian, China. DPNCheck is registered as a Class II Medical Device with the China Food and Drug Administration (CFDA) and marketed by Omron Beijing Ltd. The introduction will include exhibition, demonstrations, and technical consultations for physicians and other healthcare professionals attending the meeting.

China is dealing with an epidemic of diabetes. According to a recently published study in the *Journal of the American Medical Association* (JAMA), the prevalence of diabetes in the Chinese population has risen dramatically over the past decades to nearly 12% today. The International Diabetes Federation (IDF) estimated in 2014 that over 96 million people in China had diabetes. This represents nearly 25% of the IDF estimated worldwide population of 387 million people with diabetes.

"Omron Beijing is leading the marketing and operational planning for launch of DPNCheck in China," said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. "The launch is scheduled for selected regions late in Q4 with expansion during 2017. We believe that DPNCheck addresses an important void in the care of persons with diabetes and that China offers us a significant market opportunity."

About DPNCheck

DPNCheck is a rapid, accurate and quantitative point-of-care test to detect diabetic peripheral neuropathy, or DPN, at an early stage allowing physicians to select appropriate treatment. DPN is the most common complication of diabetes, affecting over half of people with diabetes. It causes significant morbidity including pain, increased risk of falling in the elderly, and is the primary trigger for diabetic foot ulcers which may require lower extremity amputations. DPNCheck is marketed in the U.S. to Medicare Advantage providers for profiling their patient population well as guiding treatment. It is marketed in Japan by Omron Healthcare and in Mexico by Scientia Pharma. For product information visit <http://www.DPNCheck.com/>.

China Diabetes Society

Established in 1991 in Shanghai, the Chinese Diabetes Society (CDS) is the leading national organization in the fight against the deadly consequences of diabetes in China. The mission of the CDS is to prevent, care and cure diabetes through education, research and good medical practice. The CDS has 31 provincial and municipal branch societies and more than 3,000 members across China and 6 study groups. The Society supports diabetes research, promotes awareness of diabetes to the general public, advocates on behalf of people affected by diabetes, and coordinates academic cooperation among physicians, researchers and other professionals working on diabetes.

About Omron

Omron Healthcare, headquartered in Kyoto, Japan, is a global leader in health care monitoring. The company offers a wide range of devices and services that help prevent and manage lifestyle diseases such as blood pressure monitors, body composition monitors and activity counters as well as medical devices such as vascular screening devices and visceral fat monitors in more than 100 countries. For more information on Omron Healthcare, visit www.healthcare.omron.co.jp/english/.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell®, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20161115005241/en/): <http://www.businesswire.com/news/home/20161115005241/en/>

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media